Hypertensive crisis

Cardiology in Review

Volumn 18, Issue 2, 2010, Pages 102-107

  Rodriguez, Maria Alexandra ^a   Kumar, Siva K ^a   De Caro, Matthew ^a  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

Hypertension; Hypertensive crisis; Hypertensive emergency; Hypertensive urgency

Indexed keywords

CAPTOPRIL; CLEVIDIPINE; CLONIDINE; ENALAPRILAT; ESMOLOL; FENOLDOPAM; GLYCERYL TRINITRATE; HYDRALAZINE; LABETALOL; LOOP DIURETIC AGENT; NICARDIPINE; NIFEDIPINE; NITROPRUSSIDE SODIUM; PHENTOLAMINE;

ACUTE HEART INFARCTION; ACUTE KIDNEY FAILURE; BACKACHE; BLOOD CELL COUNT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; BRAIN HEMORRHAGE; BRAZIL; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONGESTIVE HEART FAILURE; CONSCIOUSNESS DISORDER; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG EFFECT; DYSPNEA; ECLAMPSIA; ELECTROCARDIOGRAPHY; ENDOCRINE DISEASE; EPISTAXIS; FAINTNESS; HEADACHE; HEART AFTERLOAD; HEART ARRHYTHMIA; HEART PRELOAD; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; HYPERTENSION ENCEPHALOPATHY; HYPERTENSIVE CRISIS; IMMUNOHISTOCHEMISTRY; INCIDENCE; INTENSIVE CARE; KIDNEY ARTERY STENOSIS; KIDNEY INFARCTION; LUNG EDEMA; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARESTHESIA; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PHEOCHROMOCYTOMA; PHYSICAL EXAMINATION; PLASMA RENIN ACTIVITY; PREECLAMPSIA; PROGNOSIS; RACE DIFFERENCE; RENOVASCULAR DISEASE; RESTLESSNESS; REVIEW; RISK ASSESSMENT; SEIZURE; SEX DIFFERENCE; SEX RATIO; STROKE; SURVIVAL RATE; THORAX PAIN; THORAX RADIOGRAPHY; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNITED STATES; UNSPECIFIED SIDE EFFECT; URINALYSIS; WITHDRAWAL SYNDROME;

ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; EMERGENCIES; HUMANS; HYPERTENSION; PROGNOSIS; RISK FACTORS; VASODILATOR AGENTS;

EID: 77149145201     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/CRD.0b013e3181c307b7     Document Type: Review

References (68)

1. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA. 2003;290:199-206.
2. Center for Disease Control and Prevention. National Center for Health Statistics. Health, United States, 2005. Available at: http://www.cdc.gov/ bloodpressure/facts.htm.
3. Wang NY, Young JH, Meoni LA, et al. Blood pressure change and risk of hypertension associated with parental hypertension: the Johns Hopkins Precursors Study. Arch Intern Med. 2008;168:643-648.
4. Yan LL, Liu K, Matthews KA, et al. Psychosocial factors and risk of hypertension: the Coronary Artery Risk Development in Young Adults (CARDIA) study. JAMA. 2003;290:2138-2148.
5. McRae RP Jr, Liebson PR. Hypertensive crisis. Med Clin North Am. 1986;70:749-767.
6. Gifford RW. Management of hypertensive crises. JAMA. 1991;266:829-835.
7. Chobanian AV, Bakris GL, Black HR, et al. Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206-1252.
8. Volhard F, Fahr T. Die Brightsche Nierenkrankheit: Klinik Pahologie und Atlas. Berlin, Germany: Julius Springer; 1914:247-280.
9. Keith NM, Wagener HP, Keronohan JW. The syndrome of malignant hypertension. Arch Intern Med. 1928;4:264-278.
10. Oppenheimer BS, Fishberg A. Hypertensive encephalopathy. Arch Intern Med. 1928;41:264-278.
11. Gifford RW. Management and treatment of malignant hypertension and hypertensive emergencies. In: Genest J, Koiw E, Kuchel O, eds. Hypertension. New York, NY: Mc Graw Hill;1977:1024-1038.
12. Woods JW. Malignant hypertension: clinical recognition and management. Cardiovasc Clin. 1978;9:311-320.
13. Cherney D, Straus S. Management of patients with hypertensive urgencies and emergencies: a systematic review of the literature. J Gen Intern Med. 2002;17:937-945.
14. Vidt D. Severe hypertension, emergency or not? Consultant. 2007;47:649-650.
15. Varon J, Marik P. The diagnosis and management of hypertensive crises. Chest. 2000;118:214-227.
16. Rey E, LeLorier J, Burgess E, et al. Report of the Canadian Society Consensus Conference: 3. Pharmacologic treatment of hypertensive disorders in pregnancy. CMAJ. 1997;157:1245-1254.
17. Aggarwal M, Khan IA. Hypertensive crisis: hypertensive emergencies and urgencies. Cardiol Clin. 2006;24:135-146.
18. Smith CB, Flower LW, Reinhardt CE. Control of hypertensive emergencies. Postgrad Med. 1991;89:111-116.
19. Kaplan NM. Treatment of hypertensive emergencies and urgencies. Heart Dis Stroke. 1992;1:373-378.
20. Lip GY, Beevers M, Beevers DG. Complications and survival of 315 patients with malignant-phase hypertension. J Hypertens. 1995;13:915-924.
21. Zampaglione B, Pascale C, Marchisio M, et al. Hypertensive urgencies and emergencies: prevalence and clinical presentation. Hypertension. 1996;27:144-147.
22. Calhoun DA, Oparil S. Hypertensive crisis since FDR - a partial victory. N Engl J Med. 1995;332:1029-1030.
23. Martin JF, Higashiama E, Garcia E, et al. Hypertensive crisis profile: prevalence and presentation. Arq Bras Cardiol. 2004;83.
24. Bennett NM, Shea S. Hypertensive emergency: case criteria, sociodemographic profile, and previous care of 100 cases. Am J Public Health. 1988;78:636-640.
25. Wang Y, Wang QJ. The prevalence of prehypertension and hypertension among US adults according to new Joint National Committee guidelines. Arch Intern Med. 2004;164:2126-2134.
26. Gal TJ, Cooperman LH. Hypertension in the immediate postoperative period. Br J Anesth. 1975;47:70-74.
27. Halpern NA, Goldberg M, Neely C, et al. Postoperative hypertension: a multicenter, prospective, randomized comparison between intravenous nicardipine and sodium nitroprusside. Crit Care Med. 1992;20:1637-1643.
28. Van den Born BJ, Koopmans RP, Groeneveld JO, et al. Ethnic disparities in the incidence, presentation, and complications of malignant hypertension. J Hypertens. 2006;24:2299-2304.
29. Tisdale JE, Huang MB, Borzak S. Risk factors for hypertensive crisis: importance of outpatient blood pressure control. Fam Pract. 2004;21:420-424.
30. Shea S, Misra D, Ehrlich MH, et al. Predisposing factors for severe, uncontrolled hypertension in an inner-city minority population. N Engl J Med. 1992;327:776-781.
31. Ault MJ, Ellrodt AG. Pathophysiological events leading to the end-organ effects of acute hypertension. Am J Emerg Med. 1985;3(suppl 6):10-15.
32. Laragh JH, Sealey JE. The renin-angiotensin-aldosterone system and the renal regulation of sodium and potassium and blood pressure homeostasis. In: Windhager EE, ed. Handbook of Renal Physiology. New York, NY: Oxford University Press;1992:1409-1541.
33. Wallach R, Karp RB, Reves JG, et al. Pathogenesis of paroxysmal hypertension developing during and after coronary bypass surgery: a study of hemodynamic and humoral factors. Am J Cardiol. 1980;46:559-565.
34. Kincaid-Smith P. Malignant Hypertension. J Hypertens. 1991;9:893-899.
35. Guyton AC, Coleman TG, Granger HJ. Circulation: overall regulation. Annu Rev Physiol. 1972;34:13-41.
36. Lohmeier TE, Tillman LJ, Carroll RG, et al. Malignant hypertensive crisis induced by chronic intrarenal norepinephrine infusion. Hypertension. 1984;2:I177-I182.
37. Blumenfield JD, Laragh JH. Management of hypertensive crises: the scientific basis for treatment decisions. Am J Hypertens. 2001;14:1154-1167.
38. Vaughn CJ, Delanty N. Hypertensive emergencies. Lancet. 2000;356:411-417.
39. Zeller KR, Von Kuhnert L, Matthews C. Rapid reduction of severe asymptomatic hypertension: a prospective, controlled trial. Arch Intern Med. 1989;149:2186-2189.
40. Abdelwahab W, Frishman W, Landau A. Management of hypertensive urgencies and emergencies. J Clin Pharmacol. 1995;35:747-762.
41. Houston MC. The comparative effects of clonidine hydrochloride and nifedipine in the treatment of hypertensive crises. Am Heart J. 1988;115:152-159.
42. Greene CS, Gretler DD, Cervenka K, et al. Cerebral blood flow during the acute therapy of severe hypertension with oral clonidine. Am J Emerg Med. 1990;8:293-296.
43. McKindley DS, Boucher BA. Advances in pharmacotherapy: treatment of hypertensive crisis. J Clin Pharm Ther. 1994;19:163-180.
44. Handler J. Hypertensive urgency. J Clin Hypertens. 2006;8:61- 64.
45. Bertel O, Marx BE, Conen D. Effects of antihypertensive treatment on cerebral perfusion. Am J Med. 1987;82(3B):29-36.
46. Strandgaard S, Olesen J, Skinhoj E, et al. Autoregulation of brain circulation in severe arterial hypertension. BMJ. 1973;1(5852):507-510.
47. Varon J. The diagnosis and treatment of hypertensive crises. Postgrad Med. 2009;121:5-13.
48. Calhoun DA, Oparil S. Treatment of hypertensive crises. N Engl J Med. 1990;323:1177-1183.
49. Khan IA, Nair CK. Clinical, diagnostic, and management perspectives of aortic dissection. Chest. 2002;122:311-328.
50. Marik PE, Varon J. Hypertensive crises: challenges and management. Chest. 2007;131:1949-1962.
51. Pearce CJ, Wallin JD. Labetalol and other agents that block both alpha and beta-adrenergic receptors. Cleve Clin J Med. 1994;61:59-69.
52. Angaran DM, Schultz NJ, Tschida VH. Esmolol hydrochloride: an ultrashort-acting, beta-adrenergic blocking agent. Clin Pharm. 1986;5:288-303.
53. Bolognesi R, Tsialtas D, Straneo U, et al. Effects of IV nicardipine in the treatment of hypertensive crisis. Minerva Cardioangiol. 1990;38:299-303.
54. Nordlander M, Bjorkman JA, Regard HC, et al. Pharmacokinetics and hemodynamic effects of an ultra short-acting calcium antagonist. Br J Anaesth. 1996;76(suppl):A24.
55. Rodriguez G, Varon J. Clevidipine, a unique agent for the critical care practitioner. Crit Care Shock. 2006;9:37- 41.
56. Kenyon KW. Clevidipine: an ultra short-acting calcium channel antagonist for acute hypertension. Ann Pharmacother. 2009;43:1258-1265.
57. Murphy MB, Murray C, GD. Fenoldopam. a selective peripheral dopamine-receptor agonist for the treatment of severe hypertension. N Engl J Med. 2001;345:1548-1557.
58. White WB, Radford MJ, Gonzalez FM, et al. Selective dopamine-1 agonist therapy in severe hypertension: effects of intravenous fenoldopam. J Am Coll Cardiol. 1988;11:1118-1123.
59. Cohn JN, Franciosa JA, Francis GS, et al. Effect of short-term infusion of sodium nitroprusside on mortality rate in acute myocardial infarction complicated by left ventricular failure. N Engl J Med. 1982;306:1129-1135.
60. Khot UN, Novaro GM, Popovic ZB, et al. Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis. N Engl J Med. 2003;348:1756-1763.
61. Varon J. Treatment of acute severe hypertension: current and newer agents. Drugs. 2008;68:283-297.
62. Grossman E, Messerli FH, Rodzicki T, et al. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? JAMA. 1996;276:1328-1331.
63. Messerli F. Safety of calcium antagonists: dissecting the evidence. Am J Cardiol. 1996;78(suppl 9A):19-23.
64. Shepherd AM, Ludden TM, McNay JL, et al. Hydralazine kinetics in hypertensive patients after intravenous administration. Clin Pharmacol Ther. 1980;28:736-742.
65. Duley L, Henderson-Smart DJ. Drugs for rapid treatment of very high blood pressure during pregnancy. In: The Cochrane Library, Issue 1. Oxford: Update Software; 2003.
66. Bender SR, Fong MW, Heitz S, et al. Characteristics and management of patients presenting to the emergency department with hypertensive urgency. J Clin Hypertens. 2006;8:12-18.
67. Karras DJ, Kruus LK, Clenki JJ, et al. Evaluation and treatment of patients with severely elevated blood pressure in academic emergency departments: a multicenter study. Ann Emerg Med. 2006;47:230-236.
68. Varon J, Marik PE. Clinical review: the management of hypertensive crises. Crit Care. 2003;7:374-384.